Budget Impact Analysis of 13-Valent Pneumococcal Vaccine in Adult Population with Comorbidities or Immunocompromised from the Public Payer Perspective In Brazil
Value Health
.
2014 Nov;17(7):A667-8.
doi: 10.1016/j.jval.2014.08.2464.
Epub 2014 Oct 26.
Authors
C N Ferreira
1
,
D F Manfrin
2
,
C S Rufino
2
,
Y Gea
2
,
L C Haas
3
,
R A Fernandes
3
Affiliations
1
Pfizer, Inc., New York, NY, USA.
2
Pfizer, Inc., São Paulo, Brazil.
3
ANOVA, Rio de Janeiro, Brazil.
PMID:
27202438
DOI:
10.1016/j.jval.2014.08.2464
No abstract available